- Home
- SLRC vs CSTL Comparison
SLRC vs CSTL Comparison
Compare SLRC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRC
- CSTL
- Stock Information
- Founded
- SLRC 2007
- CSTL 2007
- Country
- SLRC United States
- CSTL United States
- Employees
- SLRC N/A
- CSTL N/A
- Industry
- SLRC Finance/Investors Services
- CSTL Medical Specialities
- Sector
- SLRC Finance
- CSTL Health Care
- Exchange
- SLRC Nasdaq
- CSTL Nasdaq
- Market Cap
- SLRC 771.9M
- CSTL 661.7M
- IPO Year
- SLRC 2010
- CSTL 2019
- Fundamental
- Price
- SLRC $15.18
- CSTL $33.60
- Analyst Decision
- SLRC Hold
- CSTL Strong Buy
- Analyst Count
- SLRC 6
- CSTL 6
- Target Price
- SLRC $15.96
- CSTL $38.67
- AVG Volume (30 Days)
- SLRC 336.4K
- CSTL 391.5K
- Earning Date
- SLRC 11-04-2025
- CSTL 11-03-2025
- Dividend Yield
- SLRC 10.58%
- CSTL N/A
- EPS Growth
- SLRC 1.54
- CSTL N/A
- EPS
- SLRC 1.80
- CSTL N/A
- Revenue
- SLRC $229,652,000.00
- CSTL $343,530,000.00
- Revenue This Year
- SLRC N/A
- CSTL N/A
- Revenue Next Year
- SLRC $0.23
- CSTL N/A
- P/E Ratio
- SLRC $8.61
- CSTL N/A
- Revenue Growth
- SLRC N/A
- CSTL 10.15
- 52 Week Low
- SLRC $13.64
- CSTL $14.59
- 52 Week High
- SLRC $17.94
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- SLRC 51.58
- CSTL 85.19
- Support Level
- SLRC $15.13
- CSTL $23.31
- Resistance Level
- SLRC $15.62
- CSTL $34.36
- Average True Range (ATR)
- SLRC 0.28
- CSTL 1.45
- MACD
- SLRC 0.11
- CSTL 1.09
- Stochastic Oscillator
- SLRC 71.90
- CSTL 94.10
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.